MedTrace Logo

Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years

NCT01389271 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2019-04-25

No results posted yet for this study

Summary

This is an open-label, uncontrolled, prospective long-term observation of Specific Drug in the treatment of patients with pulmonary hypertension up to 4 years. 160 patients with primary (idiopathic and familial) pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) due to scleroderma with New York Heart Association (NYHA) functional class and exercise capacity, defined as class III and IV planned to enroll. Efficacy, safety and tolerability of the drug and the survival of the patients will be observed.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Ventavis inhaled (Iloprost, BAYQ6256)

Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-03
Primary Completion
2017-03-08
Completion
2018-06-18

Countries

  • Turkey (Türkiye)

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01389271 on ClinicalTrials.gov